Pure Bioscience (PURE) Stock Statistics & Valuation Metrics

Pure Bioscience has a market cap or net worth of $8.15M. The enterprise value is $12.84M.

Pure Bioscience has 130,017,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pure Bioscience’s return on equity (ROE) is 0.47 and return on invested capital (ROIC) is -20.45%.

The current PE Ratio of Pure Bioscience is ―. Pure Bioscience’s PEG ratio is 0.15.

In the last 12 months, Pure Bioscience had revenue of 2.20M and earned -2.40M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -1.78M and capital expenditures 0.00, giving a free cash flow of -1.78M billion.

Pure Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Pure Bioscience upcoming earnings date is Nov 3, 2026, After Close (Confirmed).

Pure Bioscience as a current ratio of 1.12, with Debt / Equity ratio of -111.27%

In the past 12 months, Pure Bioscience has paid 0.00 in taxes.

Pure Bioscience EV to EBITDA ratio is 154.16, with an EV/FCF ratio of 0.16.

Pure Bioscience has $983.00K in cash and marketable securities with $6.50M in debt, giving a net cash position of -$5.51M billion.

Gross margin is 53803.55%, with operating margin of -103.18%, and net profit margin of -108.95%.

The average price target for Pure Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―